VectivBio_Logo_RGB_Color.png
VectivBio Presents Preclinical Data Supporting Apraglutide for Treatment of Acute Graft-Versus-Host Disease at the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation
23 mars 2022 07h15 HE | VectivBio AG
-- Apraglutide, a next-generation GLP-2 analog, protected against chemotherapy-induced gastrointestinal (GI) damage and improved survival in mouse models of GI acute graft-versus-host disease (aGVHD)...
VectivBio_Logo_RGB_Color.png
VectivBio to Present at the SVB Leerink 11th Annual Global Healthcare Conference
08 févr. 2022 07h15 HE | VectivBio AG
BASEL, Switzerland, Feb. 08, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for...
VectivBio_Logo_RGB_Color.png
VectivBio Announces Third Quarter 2021 Business Update
10 nov. 2021 08h30 HE | VectivBio AG
-Pivotal STARS Program of Apraglutide in SBS-IF Progressing with Majority of Sites Activated and Screening; STARS Nutrition Interim Results Expected 1H 2022- -Expanded Rare Disease Pipeline with...
VectivBio_Logo_RGB_Color.png
VectivBio to Present at the Credit Suisse 30th Annual Healthcare Conference
04 nov. 2021 07h15 HE | VectivBio AG
BASEL, Switzerland, Nov. 04, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for...
VectivBio_Logo_RGB_Color.png
VectivBio Announces Successful Opening of US IND for Apraglutide for Acute Graft-Versus-Host Disease
20 oct. 2021 07h15 HE | VectivBio AG
-FDA clears IND application for apraglutide for acute graft-versus-host disease -- Dosing of first patient expected in 1Q 2022 -- Interim data anticipated in 2H 2022 -- FDA previously granted orphan...
VectivBio_Logo_RGB_Color.png
VectivBio Announces Closing of Comet Therapeutics Acquisition
21 sept. 2021 07h15 HE | VectivBio AG
BASEL, Switzerland, Sept. 21, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for...
VectivBio_Logo_RGB_Color.png
VectivBio Announces Upcoming Investor Events
16 sept. 2021 07h15 HE | VectivBio AG
BASEL, Switzerland, Sept. 16, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for...
VectivBio_Logo_RGB_Color.png
VectivBio Appoints Scott Applebaum as Chief Legal Officer & Corporate Secretary
08 sept. 2021 07h15 HE | VectivBio AG
BASEL, Switzerland, Sept. 08, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for...
VectivBio_Logo_RGB_Color.png
VectivBio Announces Results of Extraordinary General Meeting
03 sept. 2021 07h15 HE | VectivBio AG
BASEL, Switzerland, Sept. 03, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for...
VectivBio_Logo_RGB_Color.png
VectivBio to Acquire Comet Therapeutics and Host R&D Day
31 août 2021 07h00 HE | VectivBio AG
- Acquisition of Innovative Small Molecule Platform Significantly Expands Rare Disease Pipeline -- VectivBio to Host R&D Day on September 21, 2021- BASEL, Switzerland, Aug. 31, 2021 (GLOBE...